Matches in SemOpenAlex for { <https://semopenalex.org/work/W2999996970> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W2999996970 abstract "ABSTRACT Background Paclitaxel is one of the active drugs in non-small cell lung cancer (NSCLC). Weekly paclitaxel seems less toxic and more effective compared to paclitaxel every three weeks (possibly because of the proapoptotic and angiogenic activity) the dose intensity is quiet higher with tolerable toxicities. The purpose of the study is to compare the efficacy of weekly paclitaxel to the every three weeks schedule in terms of response, toxicity profile, PFS and OS. Patients Methods Between Sep 2007 & Sep 2009, eighty patients were enrolled in the study, 40 in each group. Eligibility criteria were chemo-naiive patients, stage III & IV histologically proven NSCLC, WHO PS 0-1, adequate bone marrow, kidney & liver functions. Patients were randomized for 6-8 cycles of either weekly paclitaxel 80 mg/m2 D1,8,15 (1 hour IV infusion) and paraplatin AUC = 5 D1 (30 min IV infusion ) every 4 weeks (Group A) or paclitaxel 175 mg/m2 and paraplatin AUC = 5 every 3 weeks (Group B). Prophylactic growth factor support was allowed if indicated in Group B. Response was assessed every 2 cycles, patients who showed objective response (CR, PR, or SD) had continued to 8 cycles. Results All patients were evaluable for response, toxicity, and survival. The median age was 56 years (range 42-64) in both groups. Median WHO PS 1. Male to female ratio was 4:1. Stage III 60% & 62.5%, stage IV 40% & 37.5% in groups A & B respectively. The overall response rates ware 60% (CR 10%, PR 50%) & 40% (CR 5%, PR 35%) in groups A & B respectively. No grade IV toxicities were observed in either group. In group A & B; grade II anemia occurred in 15 & 25% of patients, grade III neutropenia was noted in 10 & 30% of patients, and grade II neuropathy occurred in 10 & 50% of patients in group A & B respectively. Median time to progression and median survival were 10 & 7 months and 14 & 11 months respectively. Conclusion Weekly paclitaxel is more effective than the every 3 weeks administration in the treatment of advanced NSCLC with higher RR, TTP, OS and better toxicity profile. Disclosure All authors have declared no conflicts of interest." @default.
- W2999996970 created "2020-01-23" @default.
- W2999996970 creator A5012956971 @default.
- W2999996970 creator A5017076342 @default.
- W2999996970 creator A5027202614 @default.
- W2999996970 creator A5087290908 @default.
- W2999996970 date "2012-09-01" @default.
- W2999996970 modified "2023-09-29" @default.
- W2999996970 title "Weekly Paclitaxel versus the Standard 3-Weekly Schedule in Patients with Non-Small Cell Lung Cancer" @default.
- W2999996970 doi "https://doi.org/10.1016/s0923-7534(20)33776-5" @default.
- W2999996970 hasPublicationYear "2012" @default.
- W2999996970 type Work @default.
- W2999996970 sameAs 2999996970 @default.
- W2999996970 citedByCount "0" @default.
- W2999996970 crossrefType "journal-article" @default.
- W2999996970 hasAuthorship W2999996970A5012956971 @default.
- W2999996970 hasAuthorship W2999996970A5017076342 @default.
- W2999996970 hasAuthorship W2999996970A5027202614 @default.
- W2999996970 hasAuthorship W2999996970A5087290908 @default.
- W2999996970 hasBestOaLocation W29999969701 @default.
- W2999996970 hasConcept C126322002 @default.
- W2999996970 hasConcept C141071460 @default.
- W2999996970 hasConcept C146357865 @default.
- W2999996970 hasConcept C151730666 @default.
- W2999996970 hasConcept C2776256026 @default.
- W2999996970 hasConcept C2776694085 @default.
- W2999996970 hasConcept C2777292972 @default.
- W2999996970 hasConcept C29730261 @default.
- W2999996970 hasConcept C71924100 @default.
- W2999996970 hasConcept C86803240 @default.
- W2999996970 hasConcept C90924648 @default.
- W2999996970 hasConceptScore W2999996970C126322002 @default.
- W2999996970 hasConceptScore W2999996970C141071460 @default.
- W2999996970 hasConceptScore W2999996970C146357865 @default.
- W2999996970 hasConceptScore W2999996970C151730666 @default.
- W2999996970 hasConceptScore W2999996970C2776256026 @default.
- W2999996970 hasConceptScore W2999996970C2776694085 @default.
- W2999996970 hasConceptScore W2999996970C2777292972 @default.
- W2999996970 hasConceptScore W2999996970C29730261 @default.
- W2999996970 hasConceptScore W2999996970C71924100 @default.
- W2999996970 hasConceptScore W2999996970C86803240 @default.
- W2999996970 hasConceptScore W2999996970C90924648 @default.
- W2999996970 hasLocation W29999969701 @default.
- W2999996970 hasOpenAccess W2999996970 @default.
- W2999996970 hasPrimaryLocation W29999969701 @default.
- W2999996970 hasRelatedWork W12145801 @default.
- W2999996970 hasRelatedWork W1966685997 @default.
- W2999996970 hasRelatedWork W1974496331 @default.
- W2999996970 hasRelatedWork W1979163504 @default.
- W2999996970 hasRelatedWork W2017544421 @default.
- W2999996970 hasRelatedWork W2056584284 @default.
- W2999996970 hasRelatedWork W2062995596 @default.
- W2999996970 hasRelatedWork W2084190613 @default.
- W2999996970 hasRelatedWork W2223685179 @default.
- W2999996970 hasRelatedWork W2329492928 @default.
- W2999996970 hasRelatedWork W2350960089 @default.
- W2999996970 hasRelatedWork W2353663633 @default.
- W2999996970 hasRelatedWork W2382420218 @default.
- W2999996970 hasRelatedWork W2392023396 @default.
- W2999996970 hasRelatedWork W2413786225 @default.
- W2999996970 hasRelatedWork W2463575118 @default.
- W2999996970 hasRelatedWork W2606932795 @default.
- W2999996970 hasRelatedWork W2967598333 @default.
- W2999996970 hasRelatedWork W3027461362 @default.
- W2999996970 hasRelatedWork W2556616803 @default.
- W2999996970 isParatext "false" @default.
- W2999996970 isRetracted "false" @default.
- W2999996970 magId "2999996970" @default.
- W2999996970 workType "article" @default.